P
Petra Pharma Corporation
Drug development company focused on therapies for serious medical conditions such as cancer and metabolic diseases
About Petra Pharma Corporation
Petra Pharma Corporation operates as a biopharmaceutical firm focused on developing treatments for cancer and metabolic diseases by targeting key cellular processes. The company was established in 2016 and originated from the work of its co-founders, Dr. Lewis Cantley and Dr. Nathanael Gray. It was launched by the life science investment and management firm, Accelerator Corporation, and headquartered in New York City.
Dr. Lewis Cantley is a cell biologist and biochemist recognized for his discovery of the phosphoinositide 3-kinase (PI3K) signaling pathway, which is crucial in understanding cancer and diabetes. His extensive research into how these biochemical pathways regulate cell growth and can lead to cancer when defective forms the scientific bedrock of Petra Pharma. Co-founder Dr. Nathanael Gray is a chemist with a background in organic chemistry and has held significant roles at Harvard Medical School and the Dana-Farber Cancer Institute. His expertise lies in discovering and validating new strategies for inhibiting anti-cancer targets. The synergy between Cantley's deep understanding of cancer metabolism and Gray's proficiency in drug discovery chemistry provided a strong foundation for the company.
The company's primary business involves the development of small molecule inhibitors that target novel enzymes central to cellular functions like cell division, growth, and signaling. By modulating these phosphoinositide (PI) signaling pathways, Petra aims to create new therapeutic options for patients. The business model is centered on advancing its scientific discoveries through preclinical and clinical development, funded by significant venture capital investment. The company secured a notable $48 million in a Series A financing round at its launch, with investors including major pharmaceutical companies like AbbVie, Eli Lilly and Company, and Pfizer Venture Investments. Total funding reached $75.5 million over two rounds. In 2022, Petra Pharma was acquired by Eli Lilly.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 54.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Apr 2020 | $28M | — | Undisclosed | — |
| SPINOUT✓Other financing | Jan 2016 | $0 | — | Harvard University | — |
Growth signals
Latest recorded traffic for Petra Pharma Corporation is 140 monthly website visits, down 39.1% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Petra Pharma Corporation in the New York City ecosystem
The Petra Pharma Corporation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- PVPfizer Ventures
Other known investors2 additional known investors
Harvard University
ARCH Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Petra Pharma Corporation on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Petra Pharma Corporation’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










